Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies (Tables)

v3.25.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2025
Summary of Significant Accounting Policies  
Schedule of significant expense categories

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

    

Six Months Ended

​

June 30, 

​

June 30, 

​

June 30, 

​

June 30, 

​

2025

    

2024

    

2025

    

2024

Operating expenses:

​

​

​

​

​

​

​

​

​

​

​

Clinical

$

1,630,084

​

$

2,048

​

$

3,447,316

​

$

4,322

Chemical, manufacturing and controls

​

558,916

​

​

25,418

​

​

694,038

​

​

68,055

Research and preclinical

​

8,094

​

​

122,565

​

​

32,228

​

​

186,280

Regulatory

​

5,628

​

​

—

​

​

27,286

​

​

(16)

Other research and development costs

​

367,221

​

​

186,053

​

​

806,073

​

​

421,160

Total research and development

​

2,569,943

​

​

336,084

​

​

5,006,941

​

​

679,801

General and administrative expenses

​

1,353,172

​

​

733,740

​

​

3,346,100

​

​

1,704,124

Total operating expenses

​

3,923,115

​

​

1,069,824

​

​

8,353,041

​

​

2,383,925

Loss from operations

​

(3,923,115)

​

​

(1,069,824)

​

​

(8,353,041)

​

​

(2,383,925)

Loss on debt conversion with related party

​

—

​

​

—

​

​

(6,134,120)

​

​

—

Interest income (expense), net

​

111,379

​

​

19,991

​

​

(35,711)

​

​

42,757

Exchange gain (loss), net

 

4,532

​

 

—

​

 

(18,742)

​

 

—

Net loss before income taxes

$

(3,807,204)

​

$

(1,049,833)

​

$

(14,541,614)

​

$

(2,341,168)